Trial site
Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, Xinjiang 830054, ChinaNot linked to an institution yet
- 15running trials
- 4closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 22 trials
- Phase 1/21 trial
- Phase 41 trial
- Status
- Active, not recruiting9 trials
- Not yet recruiting4 trials
- Completed3 trials
- Recruiting2 trials
- Terminated1 trial
- Lead sponsor
- BeiGene4 trials
- Daiichi Sankyo3 trials
- BeOne Medicines2 trials
- Amgen1 trial
- Antengene Biologics Limited1 trial
- and 8 more
Running trials
Recruiting
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
NCT07789184· Phase 3· Hua Huang, MD, PhD· Source
Contact: wenbin zhang
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Antengene Biologics Limited· Source
Contact: Yanli Qu, MD
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341· Phase 4· Eli Lilly and Company· Source
Contact: Shune Yang (principal investigator)
Recruiting
A Study of SKB518 in Patients With Lung Cancer
NCT07019675· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Contact: Chunlin Liu
Not yet recruiting
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
NCT06475599· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Guqun Shen, Master
Active, not recruiting
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036· Phase 3· Amgen· Source
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776· Daiichi Sankyo· Source
Contact: Principal Investigator
Active, not recruiting
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
NCT05652894· Phase 3· Taizhou Hanzhong biomedical co. LTD· Source
Active, not recruiting
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994· Phase 2· BeiGene· Source
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843· Phase 1/2· BeOne Medicines· Source
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297· Phase 3· BeOne Medicines· Source
Active, not recruiting
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
NCT03967977· Phase 3· BeiGene· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error